Singapore markets closed
Straits Times Index
3,293.13 +20.41 (+0.62%) S&P 500
5,070.55 +59.95 (+1.20%) Dow
38,503.69 +263.71 (+0.69%) Nasdaq
15,696.64 +245.33 (+1.59%) Bitcoin USD
66,339.48 +142.08 (+0.21%) CMC Crypto 200
1,432.41 +8.31 (+0.58%)
Lyell Immunopharma, Inc. (LYEL)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 2.4100 |
| Open | 2.3600 |
| Bid | 2.4300 x 600 |
| Ask | 2.4600 x 600 |
| Day's range | 2.3600 - 2.5500 |
| 52-week range | 1.3200 - 3.9700 |
| Volume | |
| Avg. volume | 923,211 |
| Market cap | 622.046M |
| Beta (5Y monthly) | -0.56 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9300 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.33 |
Simply Wall St.Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) market cap decline of US$89m may not have as much of an impact on institutional owners after a year of 1.4% returns
Key Insights Institutions' substantial holdings in Lyell Immunopharma implies that they have significant influence over...
ZacksLyell Immunopharma (LYEL) Is Up 28.45% in One Week: What You Should Know
Does Lyell Immunopharma (LYEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
GlobeNewswireLyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced that three abstracts of new nonclinical data have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 taking place in San Diego, CA, April 5-10. One oral and two poster presentations will highlight data fro
© 2024 Yahoo. All rights reserved.